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Abstract
Background: Most prostate cancer (PCa)-related deaths are due to metastasis, which is mediated in part by 
chemokine receptor and corresponding ligand interaction. We have previously shown that PCa tissue and cell lines 
express high levels of the chemokine receptor CXCR5, than compared to their normal counterparts, and interaction of 
CXCR5 with its specific ligand (CXCL13) promoted PCa cell invasion, migration, and differential matrix 
metalloproteinase (MMP) expression. This study dissects some of the molecular mechanisms following CXCL13-CXCR5 
interaction that mediate PCa cell migration and invasion.
Results: Using Western blot analysis, kinase-specific cell-based ELISAs, and migration and invasion assays, we show 
that PCa cell lines differentially express phosphoinositide-3 kinase (PI3K) catalytic subunit isoforms and dedicator of 
cytokinesis 2 (DOCK2). Specifically, we show that PC3 and normal prostatic epithelial (RWPE-1), but not LNCaP cell lines 
expressed DOCK2, while RWPE, PC3, and LNCaP cell lines expressed PI3K-p110α and -p110β. Moreover, PC3 selectively 
expressed PI3K-p110γ, but LNCaP and RWPE cell lines expressed PI3Kp110δ. CXCL13 caused CXCR5-dependent 
activation of the PI3Kp85α in LNCaP cells, and p85α as well as -p101 in PC3 cells. CXCL13-CXCR5 interaction regulated 
LNCaP and PC3 cell migration and invasion through extracellular signal-regulated kinase 1/2 (ERK1/2) activation that 
was primarily dependent on the PI3Kp110 isoform(s), Src, and focal adhesion kinase (FAK), but not DOCK2.
Conclusions: While additional studies will be needed to determine the PI3K-independent (i.e., DOCK2-mediated) and -
dependent events that dictate PCa cell responsiveness to CXCL13, these data provide evidence of the existence of cell 
type- and stimulus-specific signaling events that support migration and invasion of PCa cells.
Background
PCa is the second most commonly diagnosed cancer in
men after skin cancer [1,2]. Increased public awareness
and advances in diagnostic tools have helped detect this
disease at an early stage, i.e., when the tumor is localized
to the prostate gland. Unfortunately, 2.5% of patients will
suffer from metastasis and eventually die from associated
complications [3]. Patients with advanced PCa initially
respond to hormone therapy to decrease testosterone
levels, but often develop refractive tumors. In addition,
and for yet not fully defined reasons, this advanced stage
(hormone refractory) is associated with high incidences
of PCa spread to bones [4-6]. It is thought that the bone
microenvironment composition (e.g., mineralized bone
matrix, growth factors, etc.) and its physical properties
(e.g., hypoxia, acidic pH, extracellular calcium, etc.) pro-
vide a favorable milieu for tumor invasion and growth [7-
9].
Malignant cells exhibit aberrant expression of particu-
lar chemokine receptors relative to their normal counter-
parts [10-15]. We have recently shown that prostate
carcinomas differentially express CXCR5 and its expres-
sion positively correlates with stage and grade [16].
CXCR5 is a seven transmembrane G-protein coupled
receptor for the chemokine CXCL13. The CXCR5 gene is
specifically expressed in Burkitt's lymphoma and lym-
phatic tissue and plays an essential role in B cell migra-
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tion. We demonstrated that CXCR5-bearing PCa cell
lines selectively express certain MMP in response to
CXCL13 [16-18]. One means by which the bone microen-
vironment is thought to recruit PCa cells is through bone
expression of CXCL13 [19]. Thus, by virtue of its pres-
ence in the bone microenvironment, we hypothesized
that CXCL13-CXCR5 interactions help to regulate PCa
cell migration and invasion.
LNCaP and PC3 cell lines are extensively used models
to study cell signaling that may occur during PCa pro-
gression [20,21]. LNCaP cells are androgen-dependent
and express prostate specific antigen (PSA), whereas PC3
cells are androgen-independent and are unable to secrete
PSA. The acquired hormone-refractory properties have
been linked to the high skeletal metastatic potential of
PC3 cells compared to a lower potential of the hormone-
responsive LNCaP cells. These and other differences
allow LNCaP and PC3 cell systems to provide meaningful
insights into specific cellular events involved in PCa
spread to bones. In this study, we use LNCaP and PC3
cell lines to elucidate the differences in CXCR5-mediated
signaling related to cell migration and invasion, com-
pared to a normal prostatic epithelial cell line (RWPE-1).
PI3K(s) are central signaling molecules activated
through chemokine receptor-mediated signaling [22].
Chemokine receptors are coupled to heterotrimeric G
proteins α, β, and γ, which subsequently activate Class IA
and IB PI3Ks, respectively. Class IA PI3Ks consist of
three catalytic isoforms - p110α, p110β, and p110δ, which
associate with a p85α regulatory subunit, whereas Class
IB PI3Ks are comprised of p101 regulatory and p110γ
catalytic subunits. Following activation, PI3K catalyzes
the conversion of phosphoinositide 4,5-biphosphate
(PIP2) to generate phosphoinositide 3,4,5-triphosphate
(PIP3) [23-27]. This reaction can be counterbalanced by
the action of the lipid phosphatase and tensin homolog
deleted on chromosome ten (PTEN). However, PTEN is
frequently lost in PCa leading to accumulation of PIP3,
which activates Akt- and ERK-dependent signaling lead-
ing to enhanced cell migration and invasion [28-30]. On
the other hand, DOCK2, a novel member of the
Caenorhabditis elegans Ced-5, mammalian DOCK180,
and Drosophila melanogaster MyoblastCity (CDM) fam-
ily of scaffold proteins, has been shown to regulate
cytoskeletal dynamics by activating Rac isoforms [31,32]
and directing lymphocyte and neutrophil chemotaxis
[33-35]. To our knowledge, the role of DOCK2 in PCa
progression, and specifically in tumor cell migration and
invasion, has not been studied. In addition, PCa cell inva-
sion is a complex process, which also includes changes in
cell adhesion mediated in part through the FAK and Src
[36-39]. Indeed, aberrant FAK and Src activation has
been correlated with increased tumor growth and metas-
tasis following chemokine-mediated signaling. Here we
report on the role of PI3K, DOCK2, Src, and FAK in PCa
cells and reveal some of the molecular mechanisms of
CXCL13-CXCR5 interaction that mediate PCa cell inva-
sion and migration.
Results
Differential expression of PI3K isoforms and DOCK2 by 
RWPE-1, LNCaP, and PC3 cell lines
RWPE-1 and LNCaP cell lines expressed PI3Kp110α,
p110β, and p110δ, while PC3 cells expressed PI3Kp110α,
p110β, and p110γ isoforms (Figure 1A). DOCK2 was
present in RWPE-1 and PC3, but not LNCaP cell lines. To
verify the specificity of the DOCK2 siRNA, we treated
PC3 cells with 1 μg siRNA and immunoblotted for
DOCK2. Optimal silencing of DOCK2 occurred after 48
hours (Figure 1B). To demonstrate CXCL13-mediated
regulation of PI3K, we used phosphorylated PI3K regula-
tory subunit as an indicator of PI3K activation, as previ-
ously described by Cuevas et al. [40]. LNCaP and PC3 cell
Figure 1 Differential expression of PI3K catalytic isoforms and 
DOCK2 by PCa cell lines. (A) Total cell lysates (60 μg) from RWPE-1, 
LNCaP, and PC3 cells were resolved by SDS-PAGE and subjected to im-
munoblotting using antibodies against PI3Kp110α, p110β, p110γ, 
p110δ, and DOCK2 (Santa Cruz). GAPDH detection served as a loading 
control. (B) DOCK2 silencing conditions were optimized by transfect-
ing PC3 cells with 1 μg of DOCK2 siRNA duplex incubated cells for 0, 24, 
48, and 72 hours. The efficacy of DOCK2 silencing was determined by 
Western blot analysis.El Haibi et al. Molecular Cancer 2010, 9:85
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lines showed differential CXCL13-mediated activation of
PI3K regulatory subunits. CXCL13 activated only
PI3Kp85α in LNCaP cells, but phosphorylated both
PI3Kp85α and p101 subunits in PC3 cells (Figure 2).
Together, our data show differential expression and phos-
phorylation of PI3K isoforms and DOCK2 by RWPE-1,
LNCaP, and PC3 cell lines following CXCL13 stimulation.
PI3K-, Src-, FAK-dependent, and DOCK2-independent PCa 
cell migration and invasion
To determine whether activated PI3Ks, Src, and FAK pro-
moted invasiveness of PCa cells, we used corresponding
pharmacological inhibitors and assessed their effect on
cell invasion. As expected, RWPE-1 cells were completely
noninvasive in response to CXCL13 (data not shown),
while LNCaP and PC3 cells were invasive (Figure 3).
Wortmannin, PI-103 (PI3Kp110α inhibitor), and TGX221
(PI3Kp110β inhibitor) significantly reduced CXCL13-
mediated LNCaP and PC3 cell migration and invasion.
While PI3Kp110γ inhibition abrogated the ability of PC3
cells to migrate and invade, it did not affect the motility
and invasiveness of LNCaP cells. Similarly, U-73122 (G
protein β and γ inhibitor) impaired the ability of PC3, but
not LNCaP, cells to migrate and invade. Treatment of
LNCaP and PC3 cells with DOCK2 siRNA had no effect
on cell invasion. These findings show that CXCL13-
mediated LNCaP cell migration and invasion is
PI3Kp110α- and p110β-dependent, whereas PC3 cell
migration and invasion is PI3Kp110α-, p110β-, and
p110γ-, and G protein β- and γ-dependent. Src and FAK
are also key molecules involved in chemokine-mediated
signaling and promote tumor growth and metastasis
[36,39]. Src, FAK, and CXCR5 inhibition significantly
impaired PCa cell migration and invasion in response to
CXCL13 (Figure 4). This suggests that the Src-FAK axis
also plays a role in CXCR5-mediated PCa cell migration
and invasion.
ERK1/2 activation by CXCL13-treated PCa cells
G-protein coupled receptors can lead to ERK1/2 signal-
ing cascades [41]. Active (phosphorylated) levels of
ERK1/2 remained relatively low in RWPE-1 cells treated
with or without CXCL13. LNCaP cells showed reduced
basal (i.e., time 0) levels of p-ERK1/2, but significant
increases in phosphorylated (p-) ERK1/2 levels > 5 min-
utes after CXCL13 stimulation. PC3 cells, on the other
hand, had elevated basal levels of p-ERK1/2, which were
significantly elevated after CXCL13 addition (Figure 5).
These findings in part support the greater ability of PC3
cells to invade ECM than compared to LNCaP cells. Since
CXCR5 is expressed by PCa cells but not by normal pros-
tate cells, our findings also suggest that CXCL13-CXCR5
interaction regulate ERK1/2 phosphorylation in PCa
(LNCaP and PC3) cells, but not in normal prostatic epi-
thelial (RWPE) cells.
Figure 2 Differential expression and activation of PI3K regulatory 
isoforms by LNCaP and PC3 cell lines. LNCaP and PC3 cells were 
treated with CXCL13 for 0 or 5 minutes. Cell lysates were subjected to 
immunoblotting with antibodies against phospho-PI3Kp85α or phos-
pho-tyrosine following immunoprecipitation with anti-PI3Kp101 anti-
body.
Figure 3 PI3K regulation of PCa cell migration and invasion. LN-
CaP and PC3 cell lines were tested for their ability to invade Matrigel™ 
Matrix and migrate through an 8.0 μm porous membrane in the pres-
ence of CXCL13 and/or wortmannin, PI-103, TGX-221 and AS605240, 
U73122, or DOCK2 siRNA. Cells that invaded or migrated to the lower 
surface of the membrane were stained with crystal violet and counted 
by microscopy at 40× magnification. Percent cell invasion was calcu-
lated following manufacturer's instructions (BD Biosciences). Asterisks 
indicate significant differences (p < 0.05) with CXCL13-treated cells.El Haibi et al. Molecular Cancer 2010, 9:85
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PI3K-, Src-, FAK-dependent, and DOCK2-independent 
ERK1/2 regulation by PCa cells
To delineate CXCL13-CXCR5 signaling events required
for ERK1/2 activation in LNCaP and PC3 cells, we per-
formed a ERK1/2-specific fast activated cell-based ELISA
(FACE) assay in the presence of various PI3K isoform
inhibitors, DOCK2 siRNA, pertussis toxin, G protein β
and γ inhibitor, PF-573228 (FAK inhibitor), and SU6656
(Src inhibitor). CXCL13-treated LNCaP cells exhibited
an eight-fold increase in p-ERK1/2 to total ERK1/2 ratio,
compared to untreated cells (Figure 6). Treatment with
CXCR5 blockade or pertussis toxin significantly abro-
gated CXCL13-mediated ERK1/2 activation. However, G
protein β and γ inhibition did not have an effect on
ERK1/2 activation following CXCL13 stimulation of
LNCaP cells. Treatment of LNCaP cells with wortman-
nin, PI3Kp110α, PI3Kp110β, FAK, or Src inhibitors lead
to a significant reduction in ERK1/2 activation indicating
that PI3Kp110α, PI3Kp110β, FAK, and Src play a role in
LNCaP CXCL13-mediated ERK1/2 signaling. On the
other hand, PI3Kp110γ inhibition did not influence
ERK1/2 activation, suggesting CXCL13-mediated ERK1/
2 activation is PI3Kp110γ-independent in LNCaP cells.
As expected, DOCK2 siRNA had no effect on ERK1/2
activation in LNCaP cells, as these cells lack DOCK2.
CXCL13 increased the ratio of p-ERK1/2 to total
E R K 1 / 2  i n  P C 3  c e l l s .  T h e s e  r a t i o s  w e r e  s i g n i f i c a n t l y
reduced in PC3 cells following CXCR5 blockade or treat-
ment with pertussis toxin or G protein β/γ inhibitor, sug-
gesting CXCR5-mediated ERK1/2 activation can be
regulated through G protein β and/or γ subunits in
response to CXCL13 stimulation. Treatment of PC3 cells
with wortmannin, PI3Kp110α, p110β, p110γ, FAK, and
Src inhibitors lead to a significant reduction in p-ERK1/2
indicating that PI3Kp110's, FAK, and Src promote
CXCL13-mediated ERK1/2 activation. In contrast,
DOCK2 siRNA-treated PC3 cells showed comparable
Figure 4 Role of Src and FAK in PCa cell migration and invasion. 
LNCaP and PC3 cell lines were tested for their ability to invade Matri-
gel™ Matrix and migrate through an 8.0 μm porous membrane in the 
presence or absence of CXCL13, anti-human CXCR5 antibody, SU6656, 
and PF-573228. Cells that invaded or migrated to the lower surface of 
the membrane were stained with crystal violet and counted by micros-
copy at 40× magnification. Percent cell invasion was calculated follow-
ing manufacturer's instructions (BD Biosciences). Asterisks indicate 
significant differences (p < 0.05) between CXCL13-treated and untreat-
ed cells.
Figure 5 ERK1/2 Activation by CXCL13-treated PCa cells. (A) 
RWPE-1, LNCaP, and PC3 cell lines were serum starved, treated with 
100 ng/ml CXCL13 for 0, 5, 10, 15 and 30 minutes, and lysed. Cell lysates 
were subjected to immunoblotting with antibodies against p-ERK1/2. 
Membranes were stripped and reprobed with antibodies to total 
ERK1/2. (B) Densitometry analysis was performed using VersaDoc Im-
aging System (Biorad). Histograms show the differences in ERK1/2 lev-
els between LNCaP and PC3 cells at basal activity and after CXCL13 
stimulation. Asterisks indicate significant differences (p < 0.05).El Haibi et al. Molecular Cancer 2010, 9:85
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levels of p-ERK1/2 to total ERK1/2 as cells treated with
CXCL13 alone, suggesting that CXCL13-mediated ERK1/
2 activation is DOCK2-independent.
Discussion
PCa cells aberrantly express CXCR5, which plays a signif-
icant role in cell invasion, migration, and differential
matrix metalloproteinase (MMP) expression [16,18]. In
addition, it is known that metastatic PCa cells favorably
migrate to bone [4,5,42,43], which can produce CXCL13.
Hence, CXCL13-CXCR5 interaction might enable migra-
tion and invasion of PCa cells to bone. LNCaP and PC3
cell lines lack the lipid phosphatase PTEN [30,44]. As a
result of PTEN ablation, PIP3 synthesis is deregulated
leading to enhanced activation of PI3K signaling, a path-
way proposed to play a major role in tumor invasiveness
[29,44]. In this study, we show that LNCaP cells express
Class IA PI3Kp110α, p110β, and p110δ catalytic isoforms
and stimulation of these cells with CXCL13 leads to phos-
phorylation of the Class IA PI3Kp85α regulatory subunit.
In contrast, PC3 cells express the Class IB PI3Kp110γ as
well as Class IA PI3Kp110α and PI3Kp110β catalytic sub-
units and stimulation of these cells with CXCL13 leads to
phosphorylation of Class IA PI3Kp85α and Class IB
PI3Kp101 regulatory subunits.
Class IA PI3Ks are known to be activated by small G
protein α subunit(s), while Class IB PI3Ks are directly
regulated by small G protein β and γ subunits [45,46]. To
determine the physiological relevance of the different
PI3K isoforms expressed by LNCaP and PC3 cells, we
performed migration and invasion assays using cell per-
meable small molecule inhibitors of PI3Kp110α, p110β,
and p110γ which function by interacting with the adenos-
ine triphosphate-binding pocket of these enzymes [47-
53]. LNCaP cell migration and invasion were regulated by
Class IA PI3Kp110α and p110β as well as Src and FAK.
Taken together, these results provide one possible expla-
nation for LNCaP cells' reduced invasiveness and inability
to metastasize to bone. In contrast, PC3 cell migration
and invasion were Class IA (PI3Kp110α, p110β)- and
Figure 6 CXCL13-CXCR5 signaling events required for ERK1/2 activation. FACE assays were performed to measure active and total ERK1/2 levels 
in LNCaP and PC3 cell lines. Cells were treated with (or without) CXCL13 for 5 or 10 minutes, along with or without CXCR5 blockade, pertussis toxin, 
U-73122, wortmannin, PI-103, TGX221, and AS605240, DOCK2 siRNA, SU6656, and PF-573228. Experiments were performed in triplicate and results 
show the ratio of p-ERK1/2 to total ERK1/2.El Haibi et al. Molecular Cancer 2010, 9:85
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Class IB (PI3Kp110γ)-dependent. PC3 cell motility and
invasiveness was also regulated in part by Src and FAK in
response to CXCL13. In summary, CXCL13-CXCR5
interaction regulated both Src-, FAK-, and G protein β/γ-
dependent signaling cascades, which might contribute to
the high metastatic potential of PC3 cells and their ability
to spread to bone.
Price et al. demonstrated that prostate tumors contain
elevated levels of p-ERK1/2 in comparison to early-stage
or benign specimens [54]. Inhibition of ERK1/2 activa-
tion attenuates growth factor-dependent migration and
invasion of PCa cells by decreasing MMP expression [55],
suggesting a regulatory role for ERK1/2 in PCa metasta-
sis. However, factors responsible for ERK1/2 activation in
PCa cells have been incompletely defined. Here, we show
a positive role of CXCL13-CXCR5 interaction in eliciting
ERK1/2 activation in androgen-sensitive and -indepen-
dent PCa cell lines. Although basal ERK1/2 activity is
more prominent in PC3 cells than in LNCaP cells, the
activity of this kinase was significantly higher in both cell
lines in response to CXCL13 treatment. ERK1/2 activa-
tion in PCa cells was regulated by Class IA PI3K isoforms,
Src, and FAK in LNCaP cells treated with CXCL13; how-
ever, both Class IA and Class IB PI3K isoforms as well as
Src and FAK could lead to ERK1/2 phosphorylation in
PC3 cells treated with CXCL13 (Figure 7).
Chemokine-mediated leukocyte migration has also
been shown to strongly depend on the Rac activator scaf-
fold protein, DOCK2 [31]. Fukui et al. reported that
DOCK2-deficient lymphocytes have reduced ability to
migrate in response to CXCL12, CXCL13, CCL19, and
CCL21 [56]. In this study, we demonstrate that unlike
LNCaP cells, PC3 cells express DOCK2. However,
DOCK2 inhibition by siRNA did not abolish the ability of
PC3 cells to migrate and invade, nor did it modulate
ERK1/2 activation.
Conclusions
These data provide further evidence of the existence of
cell type- and stimulus-specific signaling events that sup-
port PCa cell migration and invasion. As a downstream
target of Rac GTPase, we speculate that Janus kinase -
mitogen activated protein kinase (JNK-MAPK), which is
known to be induced by CXCL13 [57], could be regulated
by DOCK2 to promote PC3 cell proliferation and anti-
apoptotic events. Future studies will be necessary to
address the precise role of DOCK2 and CXCL13-CXCR5
interaction in PCa progression. While small molecule
inhibitors effectively demonstrated the role of PI3Kp110
isoforms in CXCL13-CXCR5 signaling, the use of
PI3Kp110 isoform-specific siRNA resulted in lower cell
viability in the required time frame (data not shown).
Hence, future in vivo studies will validate the present
findings with inducible PI3Kp110 isoform-specific domi-
nant negative and constitutive active constructs
expressed by PCa cell lines as well as expand our investi-
gation of Rac isoform roles in PCa cell proliferation in
response to CXCL13. These studies will be essential to
completely dissect the PI3K-independent and -dependent
(i.e., DOCK2-mediated) events that dictate PCa cell
responsiveness to CXCL13.
Methods
Cell lines and culture
The RWPE-1 cell line (American Type Culture Collec-
tion, ATCC) was established from normal prostate epi-
thelial cells and cultured in keratinocyte serum free
media supplemented with bovine pituitary extract (0.05
mg/ml) and epidermal growth factor (5 ng/ml). The
LNCaP cell line (ATCC) was derived from the left supra-
clavicular lymph node of a metastatic prostate adenocar-
cinoma patient. The PC3 cell line (ATCC) was derived
from a bone metastasis from a grade IV prostatic adeno-
carcinoma patient. PCa cell lines were cultured in com-
plete RPMI 1640 supplemented with 10% fetal bovine
serum (FBS) and maintained in a cell culture incubator at
37°C in a humidified atmosphere with 5% CO2. All cell
lines were serum starved overnight prior to treatment
with 0 or 100 ng/ml of CXCL13 (PeproTech) in the pres-
ence or absence of: isotype control antibody or anti-
human CXCR5 antibody (1 μg/ml, R&D systems), pertus-
sis toxin (100 ng/ml, List Biological Laboratories), G pro-
tein β and γ inhibitor (U-73122, 5 μM, Sigma),
wortmannin (1 μM, Sigma), small molecule inhibitors of
Figure 7 CXCR5 activate PI3K isoforms through Gα-Src-FAK path-
way or via Gβ/γ pathway leading to subsequent activation of 
ERK1/2. LNCaP cells express PI3Kp110α, PI3Kp110β and PI3Kp110δ, 
while PC3 cells express PI3Kp110α, PI3Kp110β and PI3Kp110γ. Perhaps 
owing to their more aggressive phenotype, PC3 cells are capable of ex-
ploiting both Gα-Src-FAK and Gβ/γ-mediated events leading to en-
hanced migration and invasion, while LNCaP cells are only able to take 
advantage of the Gα-Src-FAK-mediated pathway following CXCL13-
CXCR5 interaction.El Haibi et al. Molecular Cancer 2010, 9:85
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PI3Kp110α (PI-103, 3 μM, Echelon), PI3Kp110β
(TGX221, 1 μM, Cayman Chemicals), and PI3Kp110γ
(AS605240, 3 μM, Echelon), Src (SU6656, 5 μM, Sigma),
FAK (PF-573228, 5 μM, Pfizer), or DOCK2 siRNA (1 μg,
Santa Cruz).
Treatment of cells with siRNA against DOCK2
PCa cell lines were seeded into a 6-well plate at 2 × 105
cells per well in antibiotic-free normal growth medium
supplemented with 10% FBS and incubated until 70%
confluency was achieved. Cells were then transfected
with 1 μg of DOCK2 siRNA or control siRNA duplex for
6 hours following manufacturer's protocol (Santa Cruz),
the growth medium was replaced, and cells were incu-
bated for an additional 24, 48, or 72 hours. The efficacy of
DOCK2 silencing was determined by Western blot analy-
sis.
Immunoblotting and antibodies
Following treatments, RWPE-1, LNCaP, and PC3 cell
lines were lysed in buffer containing 50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1% NP-40, protease and phosphatase
inhibitor(s) cocktail (Roche). Protein concentrations of
whole cell lysates were determined by bicinchoninic acid
(BCA) protein assay (Pierce). To determine PI3Kp101
activation, equal amounts (100 μg) of LNCaP and PC3
cell lysates were incubated at 4°C with 1 μg of anti-
PI3Kp101 antibody (Millipore) for 2 hours followed by 20
μl of Agarose A/G PLUS beads (Santa Cruz) overnight.
Immune complexes were washed twice with lysis buffer,
eluted by boiling in sample buffer for 5 minutes, and sub-
jected to immunoblot analysis.
I n  g e n e r a l ,  i m m u n o b l o t  a n a l y s i s  w a s  c o n d u c t e d  o n
immunoprecipitates generated as described above or
directly on cell lysates containing 60 μg of protein. Sam-
ples were denatured by boiling in Laemmli buffer for 5
minutes, resolved on 4-15% gradient sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE), and
transferred to nitrocellulose membranes using a semi-dry
transfer cell system (Bio-Rad). The transfer time varied
from 30 minutes to 1 hour depending on the molecular
weight of the protein being transferred. Membranes were
blocked for 1 hour at room temperature in 5% non-fat
milk in 1X T ris- T ween Buffered Saline (TTBS, 30 mM
Tris-Base, 150 mM NaCl, and 0.1% Tween 20), followed
by washing with 1× TTBS. Primary antibodies against
PI3Kp110α, PI3Kp110β, PI3Kp110γ, PI3Kp110δ,
DOCK2, phospho-PI3Kp85α (Tyr 508), phospho-
tyrosine (to detect activated PI3Kp101), p-ERK1/2, pan-
ERK1/2, and GAPDH (Santa Cruz) were added to the
membranes and incubated overnight at 4°C in 5% non-fat
milk. Membranes were then washed and corresponding
horseradish peroxidase (HRP) conjugated secondary
antibodies (Santa Cruz) were added for 1 hour followed
by additional washes. Immunoreactive proteins were
visualized by a chemiluminescent detection reagent
(Pierce) on autoradiographic films.
Migration and invasion assay
Cell migration and invasion were assessed using BD Bio-
coat™ migration or Matrigel™ invasion chamber systems
(BD Biosciences). Briefly, matrigel inserts were hydrated
for 2 hours with 500 μl of DMEM at 37°C with 5% CO2.
CXCL13 (100 ng/ml) was added to the bottom chamber
containing serum-free RPMI medium. LNCaP and PC3
cells were pretreated with isotype control or anti-human
CXCR5 antibody (1 μg/ml, R&D systems), G protein β
and γ inhibitor (U-73122, 5 μM), wortmannin (1 μM),
small molecule inhibitors of PI3Kp110α (PI-103, 3 μM),
PI3Kp110β (TGX221, 1 μM), and PI3Kp110γ (AS605240,
3 μM), Src (SU6656, 5 μM), FAK (PF-573228, 5 μM), or
DOCK2 siRNA prior to harvest, and added to the top
chambers in serum-free RPMI medium at 10,000 cells per
well. The cells were allowed to migrate or invade for 8
hours at 37°C with 5% CO2. Non-migrating cells on the
upper surface of the membrane were removed with a cot-
ton swab. The cells that migrated to the lower surface of
the membrane were fixed with methanol at room temper-
ature for 5 minutes, stained with crystal violet for 2 min-
utes, and washed with distilled water. The membranes
were peeled and placed on glass slides. Cells were then
counted by microscopy at 40× magnification and percent
cell invasion was calculated as follows: percent invasion
equals mean number of cells invading through Matrigel™
insert membrane divided by mean number of cells
migrating through control insert membrane multiplied
by 100. Experiments were performed in triplicate and
repeated three times.
Fast Activated Cell-Based ELISA (FACE) for ERK1/2
LNCaP and PC3 cell lines were cultured and seeded in
96-well plates at 5000 cells per well in complete RPMI
supplemented with 10% FBS. Cells were serum-starved
for 16 hours and pretreated with isotype control or anti-
human CXCR5 antibody (1 μg/ml), pertussis toxin (100
ng/ml), G protein β/γ inhibitor (U-73122, 5 μM), wort-
mannin (1 μM), small molecule inhibitors of PI3Kp110α
(PI-103, 3 μM), PI3Kp110β (TGX221, 1 μM), and
PI3Kp110γ (AS605240, 3 μM), Src (SU6656, 5 μM), FAK
(PF-573228, 5 μM), or DOCK2 siRNA. Following treat-
ment with inhibitors or siRNA, cells were stimulated with
(or without) CXCL13 (100 ng/ml) for 5 or 10 minutes.
Next, FACE™ assays (Active Motif) were performed to
measure modifications in the levels of p-ERK1/2 and total
ERK1/2 expression by LNCaP and PC3 cell lines. Briefly,
treated cells were fixed in 4% parafolmaldehyde in phos-
phate-buffered saline for 20 minutes. Antibody blocking
buffer was added for 1 hour, followed by anti-p-ERK1/2-El Haibi et al. Molecular Cancer 2010, 9:85
http://www.molecular-cancer.com/content/9/1/85
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or total-ERK1/2 primary antibodies. Cells were then
washed and HRP-conjugated secondary antibody was
added for 1 hour. Chemiluminescence was read using a
luminometer. After readings were recorded, cells were
stained with crystal violet for 30 minutes and absorbance
read on a spectrophotometer at 595 nm, which indicated
the relative number of cells in each well. Experiments
were performed in triplicate and results show the ratio of
p-ERK1/2 to total ERK1/2 normalized to cell density per
well.
Statistical analysis
FACE™, migration, and invasion assays were performed in
triplicate, and at least three separate studies with similar
results were performed. Images from Western blotting or
immunoprecipitation studies were visualized using Ver-
saDoc Imaging System (Biorad) prior to densitometric
quantitation. All data are presented as mean ± standard
error. Statistical analysis was performed using paired or
unpaired t tests as appropriate. A p value of < 0.05 was
considered statistically significant.
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